STL Volume 24 Number 6

3 POSTS 0 COMMENTS
Purchase PDF for $2.79
Tildrakizumab for psoriasis picture

Tildrakizumab for Moderate-to-Severe Plaque Psoriasis

Tildrakizumab is a promising therapeutic option for patients with moderate-to-severe chronic plaque psoriasis. The specificity of the drug in targeting the p19 subunit of IL-23 allows for the high efficacy and safety of long-term treatment as demonstrated in clinical trials.
Dermatologic Uses of Methotrexate image

Brief Update on Dermatologic Uses of Methotrexate

Methotrexate has been an important agent in the management of dermatologic conditions for decades. Although first indicated for the treatment of psoriasis, MTX has been shown to be a successful treatment option for a wide array of skin diseases.
Update on Drugs and Drug News

Update on Drugs & Devices: November – December 2019

The latest drug & device update covers: Trifarotene 0.005% cream (Aklief®, Galderma), Afamelanotide implant (Scenesse®, Clinuvel Pharmaceuticals), Rituximab for IV use (Rituxan®, Genentech), Jynneos™ (Bavarian Nordic), Aczone® (Almirall) and Juvéderm Voluma® XC (Allergan)

POPULAR